Viewing Study NCT05277766

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:37 PM
Ignite Modification Date: 2025-12-28 @ 1:57 PM
Study NCT ID: NCT05277766
Status: RECRUITING
Last Update Posted: 2025-07-01
First Post: 2022-02-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
Sponsor: University Hospital, Ghent
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Peritoneal Carcinomatosis View
None Peritoneal Metastases View
None Colorectal Cancer View
None Small Bowel Cancer View
None Appendix Cancer View
None Gastric Cancer View
None Pancreatic Cancer View
None Bile Duct Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PIPAC View
None Nal-IRI View
None Peritoneal carcinomatosis View
None dose-finding study View
None pharmacokinetics View
None pharmacodynamics View
None safety and efficacy View
None Onivyde View
None Primary gastrointestinal cancer View
None Colorectal cancer View
None Small bowel cancer View
None Appendix cancer View
None Stomach cancer View
None Pancreatic cancer View
None Cholangiocarcinoma View
None dose-escalation study View
None Peritoneal metastases View